Risperidone controlled release - DURECT

Drug Profile

Risperidone controlled release - DURECT

Alternative Names: Relday; Risperidone sustained release; SABER™ risperidone; ZX-003

Latest Information Update: 11 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DURECT Corporation
  • Class Antidepressants; Antineoplastics; Antipsychotics; Behavioural disorder therapies; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Bipolar disorders; Schizophrenia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Schizophrenia in USA (SC, Controlled release)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bipolar-disorders in USA (SC, Controlled release)
  • 30 Sep 2015 Pharmacokinetics and adverse events data from a phase I trial in Schizophrenia released by Zogenix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top